Clinical Trials Logo

Clinical Trial Summary

This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)


Clinical Trial Description

Patients with heart failure (HF) with reduced ejection fraction who qualify for the study will undergo a three-week run-in period in which any prior angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker they were taking will be discontinued and they will be given valsartan 80 mg bid in a single-blind fashion. After the run-in, subjects will undergo four study periods in random order. During two study periods they will receive enalapril 10 mg bid and during two they will receive sacubitril/valsartan (LCZ696) 200 mg bid for seven days. On the seventh day or each period, subjects will complete a study day in which they are randomized to receive either the bradykinin B2 receptor blocker icatibant or placebo intravenously. Each study period will be separated by a three-week washout during which subjects receive valsartan 80 mg bid. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03005184
Study type Interventional
Source Vanderbilt University Medical Center
Contact
Status Withdrawn
Phase Phase 2
Start date September 2017
Completion date January 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04452149 - Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure N/A
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Recruiting NCT05835063 - A Study to Improve Physician-Youth Communication and Medical Decision Making N/A
Completed NCT03895073 - HEart fAiluRe evaluaTion Questionnaire
Completed NCT03095196 - Multipolar CRT-d and Diabetes N/A
Recruiting NCT03180320 - Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study) N/A
Completed NCT06233695 - Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Withdrawn NCT03947853 - Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
Recruiting NCT05934487 - PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III N/A
Recruiting NCT04829617 - Promoting Well-being and Health in Heart Failure N/A
Recruiting NCT03538990 - Effect of DASH Eating Pattern on Heart Failure Outcomes N/A
Recruiting NCT05487365 - Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF N/A
Not yet recruiting NCT06270875 - Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF) N/A
Completed NCT03592836 - Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion Phase 3
Recruiting NCT05879887 - An Optimization Pilot to Optimize An Early Palliative Care Intervention for Advanced Heart Failure N/A
Not yet recruiting NCT06097481 - Narrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF) Phase 1/Phase 2
Completed NCT01560871 - Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure N/A
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Enrolling by invitation NCT05885607 - Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
Active, not recruiting NCT04012944 - SIRONA 2 Trial Heart Failure NYHA Class III N/A